Core Viewpoint - Guoke Hengtai, a leading medical device distribution service provider in China, was established on February 7, 2013, and went public on July 12, 2023, in Shenzhen Stock Exchange, focusing on medical device distribution and related professional services [1]. Group 1: Business Performance - In Q3 2025, Guoke Hengtai reported revenue of 5.353 billion, ranking 2nd out of 50 in the industry, surpassing the industry average of 1.379 billion and the median of 0.755 billion, while the top competitor, Yingke Medical, achieved revenue of 7.425 billion [2]. - The net profit for the same period was 73.27 million, ranking 27th out of 50, below the industry average of 183 million and the median of 75.88 million, with the leading company, Lepu Medical, reporting a net profit of 996 million [2]. Group 2: Financial Ratios - As of Q3 2025, Guoke Hengtai's debt-to-asset ratio was 59.50%, a decrease from 63.79% in the previous year but still above the industry average of 23.66% [3]. - The gross profit margin for Q3 2025 was 10.08%, slightly down from 10.35% year-on-year and significantly lower than the industry average of 48.78% [3]. Group 3: Executive Compensation - The chairman, Liu Bing, received a salary of 2.769 million in 2024, an increase of 473,100 from 2.296 million in 2023 [4]. - The general manager, Xiao Wei, earned 1.9887 million in 2024, up by 347,700 from 1.641 million in 2023 [4]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.47% to 17,200, while the average number of circulating A-shares held per account increased by 2.54% to 18,800 [5].